IL223955A - Pharmaceutical composition for parenteral administration which contains an omega-3 fatty acid as drug vehicle for mitigating adverse drug events - Google Patents

Pharmaceutical composition for parenteral administration which contains an omega-3 fatty acid as drug vehicle for mitigating adverse drug events

Info

Publication number
IL223955A
IL223955A IL223955A IL22395512A IL223955A IL 223955 A IL223955 A IL 223955A IL 223955 A IL223955 A IL 223955A IL 22395512 A IL22395512 A IL 22395512A IL 223955 A IL223955 A IL 223955A
Authority
IL
Israel
Prior art keywords
omega
drug
pharmaceutical composition
fatty acid
parenteral administration
Prior art date
Application number
IL223955A
Other languages
Hebrew (he)
Original Assignee
Stable Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stable Solutions Llc filed Critical Stable Solutions Llc
Publication of IL223955A publication Critical patent/IL223955A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL223955A 2010-09-10 2012-12-27 Pharmaceutical composition for parenteral administration which contains an omega-3 fatty acid as drug vehicle for mitigating adverse drug events IL223955A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/923,257 US20110071090A1 (en) 2009-03-11 2010-09-10 Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
PCT/US2011/001567 WO2012033538A1 (en) 2010-09-10 2011-09-12 Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Publications (1)

Publication Number Publication Date
IL223955A true IL223955A (en) 2016-02-29

Family

ID=44675802

Family Applications (1)

Application Number Title Priority Date Filing Date
IL223955A IL223955A (en) 2010-09-10 2012-12-27 Pharmaceutical composition for parenteral administration which contains an omega-3 fatty acid as drug vehicle for mitigating adverse drug events

Country Status (15)

Country Link
US (1) US20110071090A1 (en)
EP (1) EP2613809B1 (en)
JP (1) JP6000251B2 (en)
KR (1) KR101923192B1 (en)
CN (1) CN103200965B (en)
BR (1) BR112013004440B1 (en)
CA (1) CA2808406C (en)
ES (1) ES2760997T3 (en)
IL (1) IL223955A (en)
MX (1) MX336347B (en)
PL (1) PL2613809T3 (en)
PT (1) PT2613809T (en)
RU (2) RU2013115923A (en)
TW (1) TWI505837B (en)
WO (1) WO2012033538A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
ES2643843T3 (en) * 2011-06-15 2017-11-24 Stable Solutions Llc Therapeutic application of krill oil parenterally
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
IL249821B (en) * 2012-03-30 2019-04-30 Sancilio & Company Inc Omega-3 fatty acid ester compositions
NZ702325A (en) 2012-05-10 2016-09-30 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
EP2861227A4 (en) * 2012-06-17 2016-01-27 Matinas Biopharma Inc Omega-3 pentaenoic acid compositions and methods of use
CN103054799B (en) * 2012-10-11 2015-04-08 北京泰德制药股份有限公司 Amiodarone hydrochloride injection emulsion and preparation method thereof
CN104937103A (en) * 2012-12-06 2015-09-23 玛特纳斯生物制药有限公司 Omega-3 pentaenoic acid compositions and methods of use
WO2014143275A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
CN105939705B (en) * 2014-01-28 2020-03-17 费森尤斯卡比德国有限公司 Composition comprising triglycerides of EPA and DHA for parenteral administration
WO2015113986A1 (en) * 2014-01-28 2015-08-06 Fresenius Kabi Deutschland Gmbh Composition comprising epa and dha ethylester for parenteral administration
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
CN109843284A (en) 2016-10-11 2019-06-04 费森尤斯卡比德国有限公司 For enhancing the composition comprising EPA and DHA of anticancer agent effect
WO2018088689A1 (en) * 2016-11-08 2018-05-17 차의과학대학교 산학협력단 Composition for preventing side effects of nonsteroidal anti-inflammatory drug, and anti-inflammatory composition having no side effects

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118493A (en) * 1986-05-02 1992-06-02 Brigham And Women's Hospital Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
DE3734147C2 (en) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotonic omega-3 fatty acid-containing fat emulsion and its use
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5780451A (en) * 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
US5574065A (en) * 1994-04-21 1996-11-12 Clintec Nutrition Co. Method and composition for normalizing injury response
CA2236089C (en) * 1995-11-24 2002-03-05 Loders-Croklaan B.V. Composition based on fish oil
BR9611826A (en) * 1995-11-28 1999-07-13 Braun Melsungen Ag Lipid emulsions optimized for hydrolysis and their use
IT1277953B1 (en) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION CONTAINING L-CARNITINE OR AN ALCANOYL L-CARNITINE AND A 3-OMEGA SERIES POLYUNSATURED ACID USEFUL
EP1039893B1 (en) * 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
IT1304406B1 (en) * 1998-10-21 2001-03-19 Danital Italia S R L PREPARATION FOR THE VEHICULATION OF ACTIVE INGREDIENTS BASED ON POLYUNSATURATED ACIDIGIDS OF THE OMEGA GROUP 3.
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
EP1539104A2 (en) * 2000-12-29 2005-06-15 The Trustees Of Columbia University In The City Of New York Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
CN1728982A (en) * 2002-10-31 2006-02-01 阿尔扎公司 Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs
US7323206B1 (en) * 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
CA2545752C (en) * 2003-11-12 2013-03-26 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (pn)
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
WO2008036353A2 (en) * 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Also Published As

Publication number Publication date
ES2760997T3 (en) 2020-05-18
JP2013537192A (en) 2013-09-30
WO2012033538A1 (en) 2012-03-15
CN103200965A (en) 2013-07-10
CN103200965B (en) 2016-06-08
KR101923192B1 (en) 2018-11-28
PT2613809T (en) 2019-10-18
MX336347B (en) 2016-01-15
RU2017126315A (en) 2019-01-31
US20110071090A1 (en) 2011-03-24
TW201219057A (en) 2012-05-16
RU2013115923A (en) 2014-10-20
CA2808406C (en) 2021-03-16
PL2613809T3 (en) 2020-01-31
MX2013002725A (en) 2013-04-08
EP2613809B1 (en) 2019-07-24
JP6000251B2 (en) 2016-09-28
TWI505837B (en) 2015-11-01
CA2808406A1 (en) 2012-03-15
BR112013004440A2 (en) 2016-05-31
EP2613809A1 (en) 2013-07-17
BR112013004440B1 (en) 2021-02-09
RU2017126315A3 (en) 2020-10-30
KR20130135839A (en) 2013-12-11

Similar Documents

Publication Publication Date Title
IL223955A (en) Pharmaceutical composition for parenteral administration which contains an omega-3 fatty acid as drug vehicle for mitigating adverse drug events
IL276012B (en) Pharmaceutical compositions comprising sorbitan esters
HK1208374A1 (en) Biodegradable drug delivery for hydrophobic compositions
EP2629786A4 (en) Compositions for drug administration
EP2664328A4 (en) Omega3 fatty acid compound preparation
EP2827868B8 (en) Pharmaceutical compositions comprising fatty acid esters
PL2790699T3 (en) Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound
EP2661273A4 (en) Pharmaceutical compositions of iron for oral administration
IL226398B (en) Pharmaceutical formulations containing corticosteroids for topical administration
ZA201403195B (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
HK1206279A1 (en) Pharmaceutical compositions comprising glycerol esters
EP2825057B8 (en) Oxidixable fatty acid composition delivery form
EP2560633B8 (en) Intravenous omega-3 fatty acid compositions & method of use
IL228182B (en) Pharmaceutical composition for administration of iloprost as aerosol bolus
PL2597967T3 (en) A delivery system for active components as part of an edible composition
IL206739A (en) Injectable pharmaceutical composition containing xylitol as active ingredient therein
GB201412395D0 (en) Fatty acid ester compositions for use as emollients
PL2714042T3 (en) An analgesic pharmaceutical composition for oral administration
ZA201205978B (en) Solid pharmaceutical composition for buccal administration of agomelatine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed